title: Concomitant quantification of targeted drug delivery and biological response in individual cells.
abstract: Targeted therapies result in heterogeneous drug delivery, often with highly variable drug uptake in the targeted cells and significant numbers of cells that are essentially untargeted. However both the variably targeted cells and neighboring bystander cells may respond to the treatment. Using ionizing radiation as an example of a targeted therapeutic agent, we describe a quantitative immunofluorescence-based approach for concomitant quantification of exposure and measurement of biological responses in both targeted and bystander cells. Cultures of human skin fibroblasts are co-pulse-labeled with 3H-deoxycytidine (3H-dC) and bromodeoxyuridine (BrdU). The labeled cells, identified by BrdU immunofluorescence, are internally irradiated by low-energy beta-particles emitted by incorporated 3H-dC. BrdU immunofluorescence intensity is proportional to radioactivity incorporated and, therefore, to radiation dose rate. Cell-cycle arrest in G2 is measured in labeled cells as function of dose rate. Stress responses in bystander cells, indicated by a G1 checkpoint, are concomitantly measured with a flow cytometric-cumulative labeling index (FCM-CLI) assay. The overall approach presented herein may be useful in the context of evaluating responses to targeted drug delivery.
authors: University of Medicine and Dentistry of New Jersey, Newark, NJ 07101, USA.
authors: Massimo
authors: M
authors: Pinto
authors: Roger W
authors: RW
authors: Howell
mesh_terms: D000918:Antibody Specificity / Q000528:radiation effects; D001973:Bromodeoxyuridine / Q000378:metabolism; D024201:Bystander Effect / Q000528:radiation effects; D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis / Q000378:metabolism; D004261:DNA Replication / Q000528:radiation effects; D016503:Drug Delivery Systems; D005347:Fibroblasts / Q000166:cytology* / Q000528:radiation effects; D005434:Flow Cytometry; D016195:G2 Phase / Q000528:radiation effects; D006801:Humans; D007065:Idoxuridine / Q000378:metabolism; D011839:Radiation, Ionizing; D011874:Radiometry; D015203:Reproducibility of Results; D013194:Staining and Labeling
chemical_list: D004247:DNA; D001973:Bromodeoxyuridine; D007065:Idoxuridine
references: Nat Methods. 2005 Mar;2(3):167-9
references: 15782184
references: Radiother Oncol. 1994 Apr;31(1):1-13
references: 8041894
references: J Nucl Med. 2006 Jun;47(6):1049-58
references: 16741316
references: Pathol Oncol Res. 2006;12(2):118-24
references: 16799716
references: Radiat Prot Dosimetry. 2006;122(1-4):252-5
references: 17185313
references: Nat Methods. 2006 Aug;3(8):581
references: 16892523
references: Radiat Res. 2001 Feb;155(2):288-96
references: 11175663
references: Cancer Res. 2001 Apr 1;61(7):3039-44
references: 11306485
references: Micron. 2002;33(2):127-32
references: 11567881
references: Cytometry. 2001 Oct 15;46(5):296-306
references: 11746105
references: Curr Gene Ther. 2002 Sep;2(3):307-22
references: 12189718
references: Cytometry A. 2003 Jul;54(1):1-7
references: 12820115
references: Int J Pharm. 2003 Aug 27;262(1-2):1-11
references: 12927382
references: Curr Cancer Drug Targets. 2004 Feb;4(1):53-64
references: 14965267
references: J Immunol Methods. 1986 Oct 23;93(1):97-101
references: 3772110
references: Cytometry. 1987 Jul;8(4):372-6
references: 3113895
references: Radiat Res. 1993 Mar;133(3):289-96
references: 8451379
references: Radiat Res. 1999 Jul;152(1):88-97
references: 10428683
references: Cancer Res. 1998 May 1;58(9):2036-41
references: 9581850
references: Mutat Res. 2006 May 11;597(1-2):119-32
references: 16438994